Manipulating the Immune System in Melanoma

Manipulating the Immune System in Melanoma

Focus on Checkpoint Inhibitors and Intralesional Therapies

Not a member of My prIME? Join now for instant access.

Meeting Overview

Stay current in the rapid expansion in immunotherapies for the treatment of melanoma. Don’t miss out on expert discussions on current and emerging checkpoint inhibitors and intralesional therapies, combinations therapy options, and the latest in other immune-based therapies for the treatment of multiple melanoma disease settings.

A sponsored symposium to be held in conjunction with the 2018 SITC 33rd Annual Meeting & Pre-Conference Programs.

Not an official event of the Society for Immunotherapy of Cancer.

Date and Location

Saturday, November 10, 2018
12.30 PM – 1.30 PM

Liberty Ballroom, Salons IJKLH
Marriott Marquis
901 Massachusetts Ave NW
Washington, DC, United States



Saturday, November 10, 2018
12.30 PM – 1.30 PM



Washington, DC, United States



1.0 AMA PRA Category 1 Credit™

12.30 PM Welcome and introduction
Jeffrey S. Weber, MD, PhD
12.32 PM Oncology Guru: How much do you know about immunotherapies used to treat melanoma?
Jeffrey S. Weber, MD, PhD
12.37 PM Checkpoint inhibitor therapy in melanoma
Jeffrey S. Weber, MD, PhD
12.52 PM Intralesional therapies in melanoma
Patrick Ott, MD, PhD
1.07 PM Combining intralesional therapies and checkpoint inhibitors
Sanjiv Agarwala, MD
1.22 PM Assessing what you have learned from this activity: Have you increased your “guru” status?
Jeffrey S. Weber, MD, PhD
1.27 PM Conclusions
Jeffrey S. Weber, MD, PhD
1.30 PM Adjourn



  • Jeffrey S. Weber, MD, PhDLaura and Isaac Perlmutter Cancer Center
    NYU Langone Medical Center
    New York, New York, United States
  • Faculty

  • Sanjiv Agarwala, MDSt Luke’s University Hospital and Temple University
    Easton, Pennsylvania, United States
  • Patrick Ott, MD, PhDDana-Farber Cancer Institute
    Boston, Massachusetts, United States

*Additional faculty to be confirmed

This educational activity is specifically designed to meet the needs of medical oncologists, dermatologists, surgeons, and other healthcare professionals involved in the treatment of melanoma.

After successful completion of this educational activity, participants should be able to:

  • Assess recent efficacy and safety data on the use of immune-based therapies (eg, checkpoint inhibitors and intralesional therapies) in the management of melanoma
  • Discuss the scientific rationale for combining immune-based therapies being used to treat melanoma
  • Develop optimal treatment strategies using immune-based therapies for patients with melanoma

This educational activity is supported by a grant from Merck and Co, Inc.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Americans With Disabilities Act

Event staff will be glad to assist you with any special needs (physical, dietary, etc). Please contact Jaye Harden prior to the live event at 678.892.1353.

There is no fee for this activity.


Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.